Fig 1.
Flow diagram describing selection of studies about association between choroidal thickness and CSC status.
Table 1.
Characteristics of the included studies and quality scores on the association between choroidal thickness and CSC status.
Fig 2.
Random-effects model evaluating the association between subfoveal choroidal thickness in CSC eyes and normal control eyes.
CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 3.
Random-effects model evaluating the association between subfoveal choroidal thickness in unaffected fellow eyes and normal control eyes.
SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 4.
Meta-analysis of the association between subfoveal choroidal thickness in CSC eyes and unaffected fellow eyes.
CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI: confidence interval.
Table 2.
Mean values and standard deviations of subfoveal choroidal thickness in all studies included in the current meta-analysis.
Fig 5.
Sub-analysis based on measurement of subfoveal choroidal thickness using Spectralis SD-OCT.
(A) CSC eyes vs. normal controls, (B) Unaffected fellow eyes vs. normal controls, and (C) CSC eyes vs. unaffected fellow eyes. CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 6.
Subfoveal choroidal thickness in control eyes and in eyes with a clinical presentation of CSC determined by using Spectralis SD-OCT.
Filled circles represent mean values of subfoveal choroidal thickness (SFCT) in eyes with clinical presentation of CSC, while filled squares represent mean valued of SFCT in control eyes. Error bars indicate standard deviations. Two enlarged symbols in the right end of the figure represent the average SFCT value for each group. The dotted line represents the mid point between the lower end of the standard deviation of CSC-affected eyes and the upper end of the standard deviation of the control eyes. CSC, central serous chorioretinopathy.